Hydrochlorothiazide, but not Candesartan, Aggravates Insulin Resistance and Causes Visceral and Hepatic Fat Accumulation: The Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) Study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Treatment with angiotensin II receptor blockers is associated with lower risk for the development of type 2 diabetes mellitus compared with thiazide diuretics. The Mechanisms for the Diabetes Preventing Effect of Candesartan Study addressed insulin action and secretion and body fat distribution after treatment with candesartan, hydrochlorothiazide, and placebo. Twenty-six nondiabetic, abdominally obese, hypertensive patients were included in a multicenter 3-way crossover trial, and 22 completers (by predefined criteria; 10 men and 12 women) were included in the analyses. They underwent 12-week treatment periods with candesartan (C; 16 to 32 mg), hydrochlorothiazide (H; 25 to 50 mg), and placebo (P), respectively, and the treatment order was randomly assigned and double blinded. Intravenous glucose tolerance tests and euglycemic hyperinsulinemic (56 mU/m 2 per minute) clamps were performed. Intrahepatic and intramyocellular and extramyocellular lipid content and subcutaneous and visceral abdominal adipose tissue were measured using proton magnetic resonance spectroscopy and MRI. Insulin sensitivity (M-value) was reduced following H versus C and P (6.07±2.05, 6.63±2.04, and 6.90±2.10 mg/kg of body weight per minute, mean±SD; P ≤0.01). Liver fat content was higher ( P <0.05) following H than both P and C. The subcutaneous to visceral abdominal adipose tissue ratio was reduced following H versus C and P ( P <0.01). Glycosylated hemoglobin, alanine aminotransferase, aspartate aminotransferase, and high-sensitivity C-reactive protein levels were higher ( P <0.05) after H, but not C, versus P. There were no changes in body fat, intramyocellular lipid, extramyocellular lipid, or first-phase insulin secretion. Blood pressure was reduced similarly by C and H versus P. In conclusion, visceral fat redistribution, liver fat accumulation, low-grade inflammation, and aggravated insulin resistance were demonstrated after hydrochlorothiazide but not candesartan treatment. These findings can partly explain the diabetogenic potential of thiazides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Validation of tetrapolar bioelectrical impedance method to assess human body composition
Lukaski, H. C., Bolonchuk, W. W., Hall, C. B., & Siders, W. A. (1986) · Journal of Applied Physiology · doi:10.1152/jappl.1986.60.4.1327 · Cited by 1,370
Boden, G., & Shulman, G. I. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.3.x · Cited by 1,300
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Ramipril and the Development of Diabetes
Yusuf, S. (2001) · JAMA · doi:10.1001/jama.286.15.1882 · Cited by 541
Grassi, G., Seravalle, G., Dell'Oro, R., Trevano, F. Q., Bombelli, M., Scopelliti, F., Facchini, A., & Mancia, G. (2003) · Journal of Hypertension · doi:10.1097/00004872-200309000-00027 · Cited by 225
Cited by
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Bessone, F., Dirchwolf, M., Rodil, M. A., Razori, M. V., & Roma, M. G. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14952 · Cited by 102
Jain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32
“Other mechanisms that have been suggested are related to increases in free fatty acid levels which decrease insulin secretion in response to glucose, significant reduction in insulin sensitivity, and enhanced hepatic gluco-neogenesis in addition to catecholamine secretion [59].”
BackgroundLuther, J. M., Byrne, L. M., Yu, C., Wang, T. J., & Brown, N. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2122 · Cited by 26
Zhang, J., Tong, A., Dai, Y., Niu, J., Yu, F., & Xu, F. (2019) · The Journal of Clinical Hypertension · doi:10.1111/jch.13598 · Cited by 5
Metadata
- Authors
- Eriksson, J. W., Jansson, P.-A., Carlberg, B., Hägg, A., Kurland, L., Svensson, M. K., Ahlström, H., Ström, C., Lönn, L., Öjbrandt, K., Johansson, L., & Lind, L.
- Venue
- Hypertension
- Published
- 2008-12
- Volume
- 52
- Issue
- 6
- Pages
- 1030-1037
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2168493982
- Cited by
- 140
- References
- 8
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hydrochlorothiazide, but not Candesartan, Aggravates Insulin Resistance and Causes Visceral and Hepatic Fat Accumulation: The Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) Study. https://app.cochat.ai/papers/10.1161/hypertensionaha.108.119404
- The paper
- Eriksson, J. W., Jansson, P.-A., Carlberg, B., Hägg, A., Kurland, L., Svensson, M. K., Ahlström, H., Ström, C., Lönn, L., Öjbrandt, K., Johansson, L., & Lind, L. (2008). Hydrochlorothiazide, but not Candesartan, Aggravates Insulin Resistance and Causes Visceral and Hepatic Fat Accumulation: The Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) Study. Hypertension. https://doi.org/10.1161/hypertensionaha.108.119404
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.